EFB Dengue Literature Review

In Vitro B Cell Stimulation

13 min read

In Vitro B Cell Stimulation

Overview

In vitro B cell stimulation assays expose isolated B cell subsets to defined stimuli — polyclonal activators (CpG oligonucleotides, anti-CD40, cytokines) or antigen-specific triggers (anti-IgM crosslinking) — to assess functional properties such as proliferation, antibody secretion, cytokine production, or differentiation into plasma cells. In the context of memory B cell characterisation, these assays are used to confirm that a phenotypically defined population behaves functionally like memory cells — particularly the ability to proliferate in response to T cell-independent TLR9 stimulation without requiring BCR crosslinking.

Key Points from Literature

  • Wei et al. used CFSE dilution to assess proliferation of sorted tonsillar DN and naive B cells stimulated with CpG2006 oligonucleotide (2.5 µg/mL) + IL-2 + IL-10 for 4 days, with or without goat F(ab’)₂ anti-IgM (BCR crosslinking) (see Wei2007 - DN Memory B Cells in SLE).

  • DN cells showed significantly greater CFSE dilution (proliferation) than naive B cells in response to CpG alone (without BCR crosslinking), mirroring conventional CD27⁺ memory cells. Naive B cells required BCR crosslinking for efficient proliferation — a standard functional discriminator between memory and naive B cells (see Wei2007 - DN Memory B Cells in SLE).

  • Proliferating DN cells upregulated surface CD27 after CpG stimulation, suggesting that CD27 negativity is a plastic rather than fixed state (see Wei2007 - DN Memory B Cells in SLE).

  • EF differentiation culture (TLR7 + IFN-γ + IL-21): Jenks2018 established a minimal in vitro system for recapitulating EF B cell differentiation. FACS-sorted rNAV cells stimulated with R848 (TLR7 agonist, 1 µg/ml) + IFN-γ + IL-21 (with anti-IgM crosslinking in initial experiments) generate: aNAV cells by day 3, DN2 cells by day 3–5, and plasmablasts (IgD⁻CD27⁺CD38^hi) by day 5–7. Key findings from culture manipulations: (1) removing R848 causes >95% cell death — TLR7 is a survival signal, not merely activating; (2) substituting IL-4 for IFN-γ inhibits aNAV/DN2/PC generation; (3) adding CD40L inhibits aNAV/DN2 generation but does not affect DN1; (4) DN2 cells can generate PCs through signal 3 alone (TLR7 + IL-21 + IFN-γ) without BCR stimulation or extensive cell division (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, in vitro differentiation of sorted populations).

  • Referenced as foundational method in COVID-19 EF study: Woodruff2020 cites the Jenks2018 in vitro TLR7/IFN-γ/IL-21 EF differentiation system as the mechanistic basis for interpreting the in vivo EF pathway activation observed in severe COVID-19, but does not present new in vitro stimulation data (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • DN2 autoantibody production: DN2 cell cultures produce anti-Sm, anti-RNP, and anti-Ro autoantibodies at titers comparable to SWM cultures (LIPS assay), and generate IgG ASC frequencies comparable to SWM by ELISPOT. DN2 per-cell IgG secretion is higher than DN1 or SWM — consistent with their pre-plasmablast identity (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, ELISPOT + LIPS).

  • ★★ STIMULATION MODE IS A CONFOUND, NOT A DETAIL — soluble vs membrane-bound antigen changes the answer for atypical B cells. Early in vitro studies reported that atypical B cells have limited plasma-cell differentiation capacity, a result that shaped the field’s view of their effector potential (citing Portugal 2015 eLife; Sullivan 2015 PLoS Pathog, malaria-associated human atypical MBCs). Later work attributes this substantially to how the BCR was engaged: soluble anti-Ig fails, whereas membrane-bound anti-Ig effectively drives PC differentiation, because inhibitory receptors — FcγRIIB, and per the review FCRL5 — must be physically excluded from the B cell immune synapse for BCR signalling to proceed, which only membrane-associated antigen achieves (see Glaros2025 - Multilayered Identity of B Cell Memory, review, no original data, citing Ambegaonkar 2020 Sci Adv).

    Verification note (2026-08-16). The primary abstract was independently checked at ingest because the review’s paraphrase and the paper’s title read in opposite directions. Direction confirmed: atypical MBCs “are unable to respond to soluble antigens” but “robustly respond to antigens that associate with cell surfaces, such as antigens in immune complexes.” The title’s “restricts responses to membrane-associated antigens” means responses are restricted to that antigen form.

  • ⚠ Design consequence for dengue assays. In vitro restimulation of patient B cells with soluble DENV E or NS1 would systematically under-report the functional capacity of the atypical/DN2 population this wiki tracks. A membrane-associated or immune-complexed antigen arm is the informative comparator, and any negative result from soluble antigen alone should not be reported as evidence of impaired function.

  • Other stimulation caveats from the same review. GC B cell fate, unlike PC fate, cannot be induced simply by reducing stimulus strength — PC differentiation is readily induced in vitro by anti-IgM or anti-CD40 plus cytokines, whereas GC specification requires a more complex regulatory framework; and transient removal of anti-CD40 antibody was sufficient to induce BCL6 upregulation in cultured B cells, suggesting interruptions in CD40 signalling rather than signal strength bias toward the GC programme (see Glaros2025 - Multilayered Identity of B Cell Memory, review).

  • The Naradikian two-signal in vitro system: TLR poising → IFN-γ/IL-21, T-bet readout from 12 h, before first division. The murine minimal in vitro system for ABC generation: TLR7 or TLR9 ligand poises naive B cells for ABC fate, and this poising must be followed by IFN-γ or IL-21 to complete differentiation; neither BCR ligation alone nor with CD40 costimulation substitutes. Coculture experiments established that both the TLR-poising requisite and the cytokine requisite are cell-intrinsic. T-bet expression is detectable within 12 hours — before the first cell division — arguing against a purely epigenetic mechanism (see Cancro2020 - Age-Associated B Cells, review — no original data, citing Naradikian et al. 2016; mouse, in vitro). This is the murine methodological precedent for the human TLR7+IFN-γ+IL-21 differentiation protocol already on this page from Jenks2018 - DN2 B Cells and EF Pathway in SLE.

  • The BCR-refractory-but-viable signature is a distinguishing functional assay readout for ABCs. ABCs do not divide in response to BCR cross-linking (unlike FO B cells) but remain viable under those conditions (unlike MZ and transitional B cells, which die rapidly) — BCR cross-linking synergises with, but cannot substitute for, TLR7/9 stimulation. This proliferation/viability signature is a functional assay readout that distinguishes ABCs from FO, MZ, and transitional B cell subsets in stimulation experiments (see Cancro2020 - Age-Associated B Cells, review — no original data; mouse).

  • Cytokine output depends entirely on the stimulation used — two studies, opposite answers. DN B cells could not be induced to express IL-10 or TNF-α after total B cell stimulation with anti-CD40 + IL-4, or CpG/PMA/ionomycin (citing Bulati 2011). Under CD40L stimulation of total B cells from HD and MS patients, the review’s own authors found DN cells producing lymphotoxin-α and TNF-α, with LTα⁺ frequencies similar to — and TNF-α⁺ frequencies higher than — SM cells (see Beckers2023 - Origins and Functions of DN B Cells, review, own data). A negative cytokine result from one stimulation condition is therefore uninformative about the population’s capacity.

  • Granzyme B requires IL-21 + anti-BCR. DN B cells of young and elderly HD and of MS patients produced granzyme B after in vitro IL-21 + anti-BCR stimulation — a cytotoxic output not captured by any of the proliferation or ASC-differentiation protocols already on this page (see Beckers2023 - Origins and Functions of DN B Cells, review, own data; see Atypical B Cell Effector Output).

  • Triple stimulation is the condition that works across donor ages. Where CpG alone or anti-BCR+anti-CD40 alone gave age-dependent or irreproducible proliferation, CpG + anti-BCR + anti-CD40 strongly activated DN B cells of both young and elderly HD. If the experimental question is “can these cells respond at all,” triple stimulation is the appropriate positive control (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Martorana 2014).

  • DN1 responds to the DN2 differentiation cocktail. GC-dependent DN1 cells differentiate into ASCs in vitro under the same TLR7 + BCR ligation + IFN-γ + IL-21 protocol described above for DN2. Whether DN1’s ASC differentiation is TLR7- or BCR-dependent is unresolved — the protocol as written cannot separate them (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Jenks 2018).

  • ★ Testing sufficiency by adding back the suspected blocker to wild-type cells. The standard design tests necessity by knocking a gene out. Stone additionally tested sufficiency: having found that Tbx21^−/−^ B cells retain an inflammatory NF-κB/TLR programme and fail to make ASCs, the authors added an NF-κB activator (betulinic acid) or TLR7/9 ligands (R848, CpG) to wild-type Be1 cultures from day 2 and reproduced the ASC defect — with a proliferation control confirming cells expanded equally well (see Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation, mouse, in vitro). The knockout shows the brake is needed; the add-back shows the un-restrained programme is enough to cause the phenotype. Worth copying whenever a stimulation experiment attributes a differentiation failure to a signalling programme.

  • Timed two-step addition distinguishes priming from execution. Reagents were added from day 2 of a 4-day culture rather than at initiation, separating effects on early activation and proliferation from effects on terminal differentiation (see Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation, mouse, in vitro). Compare the days 0–3 / days 3–6 temporal split used in the human system of Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation — the same lab applying the same logic across species.

  • ★ The two-step, wash-and-reculture design that separates priming from differentiation. Purified B cells were cultured at 1×10⁶/ml for 3 days with anti-Ig (5 µg/ml), R848 (5 µg/ml), IL-2 (50 U/ml), BAFF (10 ng/ml), IL-21 (10 ng/ml) and IFN-γ (20 ng/ml) (Step 1), then washed and recultured at 2×10⁵/ml for 3 more days with the same stimuli (Step 2), with output normalised to cell input (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human, n=20 HD + n=40 SLE + in vitro reconstruction). Two things make this design unusually informative: an “all minus one” omission run separately in Step 1, Step 2, or both, which is what localised IFN-γ to the priming window and IL-21 to the differentiation window; and R848 dose titration, which showed IFN-γ synergises with a 100-fold lower TLR7/8 dose. The wash-and-reculture step is essential — without it, a factor’s early and late roles cannot be distinguished.

  • ★ An APC-supplemented CpG/IL-2 system in which cytokine blockade separates proliferation from differentiation. Resting allogeneic CD19⁺ B cells (Miltenyi CD19 beads, ≥95% purity) were CFSE-labelled and cultured 6 days in 96-well plates at a 5:1 B-cell-to-APC ratio with DENV-2-infected (MOI 1, 48 h) CD14⁺ monocytes or monocyte-derived DCs, plus IL-2 at 20 U/ml and CpG type B 2006 at 50 nM. Readouts: CFSE dilution, CD19/CD20, the CD27⁺⁺CD38⁺⁺ gate (22.8% of total B cells with infected monocytes vs 3.83% with B cells alone), and day-6 IgG/IgA/IgM ELISA on supernatant. Blocking antibodies added to the same wells dissociated the two outputs: anti-IL-10 and anti-IP-10 both cut proliferation, but only anti-IL-10 blocked plasmablast differentiation and IgM secretion; anti-BAFF and TACI-Fc modestly reduced both, with TACI-Fc significantly reducing IgM; anti-IL-6 did neither (see Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue, in vitro, 4 independent experiments with 4 healthy blood donors). Effect sizes live in supplementary Figure S5, which is not in the wiki’s PDF — only the authors’ qualitative wording (“modestly diminished”, “significantly reduced”) is quoted here.

  • ⚠ Three design caveats before borrowing this protocol. (i) The coculture is allogeneic — monocytes and B cells come from different donors — so a mixed-lymphocyte component runs alongside the monocyte effect. (ii) CpG supplies a TLR9 signal in every arm, including the B-cells-alone control, so the assay measures what the APC adds on top of TLR9 + IL-2, not APC help in isolation. (iii) There is no antigen-specific readout; all antibody measurements are total isotype. Note also the relation to the Wei2007 - DN Memory B Cells in SLE system above, which uses the same CpG2006 + IL-2 backbone with IL-10 added as an exogenous stimulant — Kwissa’s result that removing IL-10 abolishes plasmablast differentiation is the necessity counterpart to that addition, and the two agree in direction.

  • R848 used as the readout stimulus rather than the differentiation stimulus — the inverse of the usual DN2 induction design. Sorted murine B cell subsets were cultured 72 hours in complete media containing R848 (10 ng/mL) before supernatant collection for a 95-antigen autoantigen microarray, and the same ligand was used for 72-hour ELISpot against an overnight media-only arm. Because the populations were generated in vivo and R848 was applied only afterwards, this design asks what a population can secrete, not what drives its formation (see Song2022 - Tfh Outside Germinal Centers Drive T-bet CD11c B Cells, mouse, LCMV-Armstrong). A second, incidental in vitro result is load-bearing for study design: activated B cells increased CD11c-DTR transgene expression independently of Itgax, which is why the CD11c-DTR system cannot be used to deplete CD11c⁺ B cells early after infection.

Contradictions & Debates

  • ⚠ The CpG/TLR9 proliferation assay does not reproduce across laboratories. Four studies of DN B cell proliferation to CpG return four different answers (no response; response in young but not elderly; response at switched-memory levels; no response with anti-BCR+CpG+IL-4). Beckers2023 - Origins and Functions of DN B Cells attributes the spread to differing proliferation markers, stimulation conditions, and healthy-donor cohorts, and treats DN responsiveness as an open question rather than a settled property. Methodological consequence: proliferation readouts for this compartment are not comparable across papers unless marker, cocktail, and donor age distribution are matched. See TLR9 and Double-Negative B Cell Contradictions.
  • Activation-marker readouts and signalling readouts disagree on the same cells. DN cells show a decreased percentage of CD86⁺ activated cells after triple or CD40L stimulation relative to total B cells (HD and MS) — yet DN1-3 cells from HD, COVID-19 patients and vaccinees all maintain BCR signalling by phospho-flow after IgG stimulation, with DN2 showing the largest signalling capacity. Whether DN cells are “hyporesponsive” is a function of which assay is run (see Beckers2023 - Origins and Functions of DN B Cells, review, own data + citing Castleman 2022; Phospho-Flow Cytometry).

Double-Negative B Cell, DN2 B Cell, Activated Naive B Cell, Plasmablast, Memory B Cell, CD27, TLR7, Extrafollicular Response, FCRL5, Atypical B Cell, Age-Associated B Cell, DN2 B Cell

Sources

Graph View

Backlinks